Efficacy and Safety of Danirixin (GSK1325756) Co-administered With Standard-of-Care Antiviral (Oseltamivir): A Phase 2b, Global, Randomized Study of Adults Hospitalized With Influenza
Anuradha Madan, Shuguang Chen, Phillip Yates, Michael L Washburn, Grace Roberts, Andrew J Peat, Yu Tao, Michael F Parry, Otis Barnum, Micah T McClain, Sumita Roy-Ghanta, Anuradha Madan, Shuguang Chen, Phillip Yates, Michael L Washburn, Grace Roberts, Andrew J Peat, Yu Tao, Michael F Parry, Otis Barnum, Micah T McClain, Sumita Roy-Ghanta
Abstract
Background: Excessive neutrophil migration has been correlated with influenza symptom severity. Danirixin (GSK1325756), a selective and reversible antagonist of C-X-C chemokine receptor 2, decreases neutrophil activation and transmigration to areas of inflammation. This study evaluated the efficacy and safety of intravenous (IV) danirixin co-administered with oseltamivir for the treatment of adults hospitalized with influenza.
Methods: In this phase 2b, double-blind, 3-arm study (NCT02927431), influenza-positive participants were randomized 2:2:1 to receive danirixin 15mg intravenously (IV) twice daily (bid) + oral oseltamivir 75mg bid (OSV), danirixin 50mg IV bid + OSV, or placebo IV bid + OSV, for up to 5 days. The primary endpoint was time to clinical response (TTCR).
Results: In total, 10 participants received study treatment (danirixin 15mg + OSV, n = 4; danirixin 50mg + OSV, n = 4; placebo + OSV, n = 2) before the study was terminated early due to low enrollment. All participants achieved a clinical response. Median (95% confidence interval) TTCR was 4.53 days (2.95, 5.71) for danirixin 15mg + OSV, 4.76 days (2.71, 5.25) for danirixin 50mg + OSV, and 1.33 days (0.71, 1.95) for placebo + OSV. Adverse events (AEs) were generally of mild or moderate intensity; no serious AEs were considered treatment-related. Interleukin-8 levels increased in nasal samples (using synthetic absorptive matrix strips) and decreased serum neutrophil-elastase-mediated degradation of elastin decreased in danirixin-treated participants, suggesting effective target engagement.
Conclusions: Interpretation of efficacy results is restricted by the low participant numbers. The safety and tolerability profile of danirixin was consistent with previous studies.
Clinical trial information: The registration data for the trial are in the ClinicalTrials.gov database, number NCT02927431, and in the EU Clinical Trials Register (https://www.clinicaltrialsregister.eu/) as GSK study 201023, EudraCT 2016-002512-40. Anonymized individual participant data and study documents can be requested for further research from www.clinicalstudydatarequest.com.
Keywords: CXCR2 antagonist; danirixin; hospitalization; influenza; neutrophils.
Figures
References
- Blanton L, Alabi N, Mustaquim D, et al. . Update: influenza activity in the United States during the 2016–17 season and composition of the 2017–18 influenza vaccine. MMWR Morb Mortal Wkly Rep 2017; 66:668–76.
- Narasaraju T, Yang E, Samy RP, et al. . Excessive neutrophils and neutrophil extracellular traps contribute to acute lung injury of influenza pneumonitis. Am J Pathol 2011; 179:199–210.
- Short KR, Kroeze EJBV, Fouchier RAM, Kuiken T. Pathogenesis of influenza-induced acute respiratory distress syndrome. Lancet Infect Dis 2014; 14:57–69.
- Hayden FG, Fritz R, Lobo MC, et al. . Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J Clin Invest 1998; 101:643–9.
- Busch-Petersen J, Carpenter DC, Burman M, et al. . Danirixin: a reversible and selective antagonist of the CXC chemokine receptor 2. J Pharmacol Exp Ther 2017; 362:338–46.
- Washburn M, Crosby R, Remlinger K, et al. . Therapeutically attenuating neutrophil recruitment with a CXCR2 antagonist in combination with oseltamivir ameliorates influenza induced lung injury and disease [published online ahead of print March 7, 2019). Open Forum Infect Dis. 2019; doi:10.1093/ofid/ofz106.
- Miller BE, Mistry S, Smart K, et al. . The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756)–a selective CXCR2 antagonist –in healthy adult subjects. BMC Pharmacol Toxicol 2015; 16:18.
- Roberts G, Chen S, Yates P, et al. . A randomized, double-blind, placebo-controlled study of the safety, tolerability and clinical effect of oral danirixin in the treatment of healthy adults with acute, uncomplicated influenza. Open Forum Infect Dis. (accepted for publication, OFID-D 18–0069)
- Lazaar AL, Miller BE, Tabberer M, et al. . Effect of the CXCR2 antagonist danirixin on symptoms and health status in COPD. Eur Respir J 2018; 52: 1801020. doi: 10.1183/13993003.01020-2018.
- Jefferson T, Jones M, Doshi P, et al. . Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014; 348:g2545.
- European Centre for Disease Prevention and Control. Summary of the influenza 2016–2017 season in Europe. Available at:
- Fiore AE, Fry A, Shay D, et al. ; Centers for Disease Control and Prevention (CDC) Antiviral agents for the treatment and chemoprophylaxis of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1–24.
- McGeer A, Green KA, Plevneshi A, et al. ; Toronto Invasive Bacterial Diseases Network Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007; 45:1568–75.
- Lee N, Choi KW, Chan PK, et al. . Outcomes of adults hospitalised with severe influenza. Thorax 2010; 65:510–5.
- de Jong MD, Ison MG, Monto AS, et al. . Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients. Clin Infect Dis 2014; 59:e172–85.
- Marty FM, Vidal-Puigserver J, Clark C, et al. . Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial. Lancet Respir Med 2017; 5:135–46.
- Garg S, Jain S, Dawood FS, et al. . Pneumonia among adults hospitalized with laboratory-confirmed seasonal influenza virus infection-United States, 2005-2008. BMC Infect Dis 2015; 15:369.
- Jurcevic S, Humfrey C, Uddin M, et al. . The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions. Br J Clin Pharmacol 2015; 80:1324–36.
- Moss RB, Mistry SJ, Konstan MW, et al. ; CF2110399 Investigators Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis. J Cyst Fibros 2013; 12:241–8.
- Thatcher TH, McHugh NA, Egan RW, et al. . Role of CXCR2 in cigarette smoke-induced lung inflammation. Am J Physiol Lung Cell Mol Physiol 2005; 289:L322–8.
- Miller BE, Smart K, Mistry S, et al. . The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers. Eur J Drug Metab Pharmacokinet 2014; 39:173–81.
Source: PubMed